Compare Biogen Inc (BIIB) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Valero Energy Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Valero Energy Corporation trades at $330.25 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 3.1× Biogen Inc's market cap, and Valero Energy Corporation pays a 1.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VLO | |
|---|---|---|
Market Cap | $30.13B | $93.27B |
Sector | Health | Energy |
52-Week High | $216.63 | $323.92 |
52-Week Low | $128.93 | $133.38 |
Enterprise Value | $37.20B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Valero Energy (VLO) trades at $329.99, up 4.78% on the day, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals indicate robust profitability with a 29.31% ROE and a P/E of 13.51. Recent news highlights refining strength and geopolitical factors benefiting the sector.
Outlook remains positive with analyst consensus favoring a Buy rating and a $324.27 price target. Key risks include volatile oil prices and refining margin pressures, but disciplined capital allocation and renewable diesel growth offer upside potential for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
